Glenmark pharma share price

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. It operates through the India, North America, Latin America, Europe, and Rest of the World geographical segments. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India. Glenmark Pharma has completed a long-term inverted Head & shoulders pattern. It is now looking bullish with an upside move of INR 500 from current levels. Almost 2x. At present it is at the 0.5 resistance level of the Fibonacci chart Glenmark Pharma has completed a long-term inverted Head & shoulders pattern. It is now looking bullish with an upside move of INR 500 from current levels. Almost 2x. At present it is at the 0.5 resistance level of the Fibonacci chart One can accumulate this in range of 550-650 with the Sl Of ₹490 and Target of 950 and 1050 good breakout can be seen on a quaterly chart.. lets see if it sustains One can accumulate this in range of 550-650 with the Sl Of ₹490 and Target of 950 and 1050 good breakout can be seen on a quaterly chart.. lets see if it sustains In Gujarati “ Bhav is Bhagwan ” Disclaimer : I am not a SEBI registered Analyst. Please do your own Analysis before taking any trade/investment. The above view is just for educational purpose only. In Gujarati “ Bhav is Bhagwan ” Disclaimer : I am not a SEBI registered Analyst. Please do your own Analysis before taking any trade/investment. Th...

Profile Summary Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes. Directors • Glenn SaldanhaCHM (50) • V. S. ManiCFO • Harish KuberCCO • Cherylann PintoEDR • Blanche SaldanhaNED • Dipankar BhattacharjeeNID (58) • Rajesh DesaiNID (57) • Sridhar GorthiNID (49) • Devendra MehtaNID (84) • Bernard MunosNID • Sona RamasastryNID • Brian TempestNID An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glenmark Pharmaceutical...

• Stock Returns vs Nifty Midcap 100 Stock gave a 3 year return of 63.43% as compared to Nifty Midcap 100 which gave a return of 145.85%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated 63.43% return as compared to Nifty Pharma which gave investors 29.91% return over 3 year time period. (as of last trading session) NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 57.47 1.84 3.13 13.84 1.53 7.13 15.27 2.90 10.53 1.96 0.46 0.00 25.08 4.90 19.56 24.37 10.31 28.36 21.09 13.18 14.69 1.42 0.49 0.00 31.42 3.83 11.07 13.41 6.35 16.25 11.75 8.23 15.04 0.88 0.58 0.00 32.01 5.55 17.35 21.21 12.56 12.61 20.06 15.71 45.89 2.49 0.00 0.00 39.58 3.15 8.06 11.59 5.46 10.43 12.66 7.87 18.58 2.87 0.25 0.00 Add More • Stock Returns vs Nifty Midcap 100 Stock gave a 3 year return of 63.43% as compared to Nifty Midcap 100 which gave a return of 145.85%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated 63.43% return as compared to Nifty Pharma which gave investors 29.91% return over 3 year time period. (as of last trading session) Meeting Date Announced on Purpose Details May 19, 2023 May 03, 2023 Board Meeting Audited Results & Final Dividend Feb 10, 2023 Jan 13, 2023 Board Meeting Quarterly Results Nov 11, 2022 Nov 02, 2022 Board Meeting Quarterly Results Aug 10, 2022 Jul 29, 2022 Board Meeting Quarterly Results May 27, 2022 May 18, 2022 Board Meeting Audited ...

NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 15.78 3.45 21.83 28.62 17.28 12.10 29.11 21.60 38.11 3.67 0.00 0.00 23.53 4.04 17.40 13.36 10.42 15.73 25.56 22.20 28.10 1.73 0.38 0.00 13.68 2.49 18.22 24.04 10.53 19.54 16.46 11.44 21.05 1.42 0.37 0.00 -105.43 1.19 -1.12 2.77 -0.54 1.66 4.14 -1.22 -3.83 2.12 0.63 0.00 -28.48 12.36 -43.40 -33.00 -26.81 41.83 -90.02 -93.21 -7.82 2.54 0.00 0.00 Add More Meeting Date Announced on Purpose Details Apr 27, 2023 Apr 19, 2023 Board Meeting Audited Results Mar 16, 2023 Mar 09, 2023 Board Meeting Interim Dividend Jan 27, 2023 Jan 13, 2023 Board Meeting Quarterly Results Oct 21, 2022 Oct 14, 2022 Board Meeting Quarterly Results Aug 04, 2022 Jul 22, 2022 Board Meeting Quarterly Results • About Glenmark Life Glenmark Life Sciences Ltd., incorporated in the year 2011, is a Small Cap company (having a market cap of Rs 7,372.46 Crore) operating in Pharmaceuticals sector. Glenmark Life Sciences Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2022. For the quarter ended 31-03-2023, the company has reported a Standalone Total Income of Rs 624.16 Crore, up 14.03 % from last quarter Total Income of Rs 547.34 Crore and up 20.23 % from last year same quarter Total Income of Rs 519.15 Crore. Company has reported net profit after tax of Rs 146.36 Crore in latest quarter. The company’s top management incl...

Insider Monkey Top 15 Pharmaceuticals Companies in India In this article, we will take a look at the top 15 pharmaceutical companies in India. For more companies, click Top 5 Pharmaceutical Companies in India. India is the largest producer of generic medications and vaccines worldwide. It makes up about 20% of the entire amount of generic drug supply in the world. With almost 200 […] Reuters India's Glenmark Pharma weighs selling stake in Glenmark Life - Mint India's Glenmark Pharmaceuticals Ltd is considering selling a majority of the 82% stake it holds in Glenmark Life Sciences Ltd as it looks to lower its debt load, the Mint business daily reported on Tuesday. Glenmark Pharma has hired Kotak Mahindra Capital Co Ltd to oversee the sale of its stake in Glenmark Life and has contacted buyout funds to gauge interest, Mint reported, citing two people familiar with the matter. Glenmark Pharma, Glenmark Life, which makes active pharmaceuticals ingredients (APIs) for drugs, and Kotak did not immediately respond to Reuters' request for comment.

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.;

• Adani Enterp. 2460.50 ↑ 9.35 (0.38%) • Adani Ports 742.90 ↑ 7.95 (1.08%) • Apollo Hospitals 4942.35 ↑ 15.65 (0.32%) • Asian Paints 3185.75 ↑ 5.20 (0.16%) • Axis Bank 974.95 ↑ 0.20 (0.02%) • B P C L 366.80 ↑ 7.35 (2.04%) • Bajaj Auto 4770.55 ↑ 27.15 (0.57%) • Bajaj Finance 7096.15 ↑ 59.00 (0.84%) • Bajaj Finserv 1466.80 ↑ 0.30 (0.02%) • Bharti Airtel 835.95 ↑ 2.45 (0.29%) • Britannia Inds. 4893.15 ↑ 14.40 (0.30%) • Cipla 970.40 ↑ 1.15 (0.12%) • Coal India 228.50 ↑ 0.85 (0.37%) • Divi's Lab. 3449.00 ↑ 20.25 (0.59%) • Dr Reddy's Labs 4685.25 ↑ 18.45 (0.40%) • Eicher Motors 3590.05 ↑ 8.75 (0.24%) • Grasim Inds 1727.10 ↑ 11.35 (0.66%) • H D F C 2642.80 ↓ -10.10 (-0.38%) • HCL Technologies 1136.90 ↑ 27.15 (2.45%) • HDFC Bank 1603.40 ↓ -7.20 (-0.45%) • HDFC Life Insur. 583.20 ↑ 1.50 (0.26%) • Hero Motocorp 2925.95 ↑ 26.65 (0.92%) • Hind. Unilever 2650.55 ↑ 14.35 (0.54%) • Hindalco Inds. 418.30 ↑ 3.25 (0.78%) • ICICI Bank 936.70 ↓ -1.35 (-0.14%) • IndusInd Bank 1330.95 ↓ -0.10 (-0.01%) • Infosys 1292.80 ↑ 26.85 (2.12%) • ITC 435.95 ↓ -2.50 (-0.57%) • JSW Steel 748.90 ↑ 0.40 (0.05%) • Kotak Mah. Bank 1875.80 ↑ 3.80 (0.20%) • Larsen & Toubro 2342.65 ↓ -20.35 (-0.86%) • M & M 1381.45 ↑ 10.80 (0.79%) • Maruti Suzuki 9550.00 ↓ -77.80 (-0.81%) • Nestle India 22224.90 ↑ 151.45 (0.69%) • NTPC 186.00 ↑ 3.20 (1.75%) • O N G C 155.05 ↑ 0.80 (0.52%) • Power Grid Corpn 242.45 ↓ -2.45 (-1.00%) • Reliance Industr 2483.45 ↑ 1.50 (0.06%) • SBI Life Insuran 1248.20 ↑ 15.80 (1.28%) • St Bk of Indi...

Glenmark Pharmaceuticals share price fell over 3 percent intraday to Rs 516.45 on November 16 after foreign broking house Morgan Stanley kept "underweight" rating on the stock with the target at Rs 554. The core business should grow in the low to mid-teens and margin should be stable, however, cash conversion and specialty monetisation are the key value drivers, it said. Glenmark Pharmaceuticals has been listed in the Dow Jones Sustainability Index (DJSI) under the category of emerging markets for the fourth consecutive year, the company said in a release on November 16. Inclusion in this list is considered highly prestigious by global investors, financial analysts and other stakeholders and serves as a benchmark for investors who integrate sustainability considerations into their portfolios, it added. “Our inclusion in the coveted Dow Jones Sustainability Indices (DJSI) for the fourth consecutive year is a validation of our commitment to sustainability and reiterates our consistent performance across all sustainability indicators," said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals. "The DJSI inclusion strengthens our resolve to uphold our sustainability strategy that encompasses the Environmental, Social and Governance (ESG) principles to make a positive difference to our operations, stakeholders, communities and the planet at large." Catch all the market action on our live blog Here is what other brokerages have to say about the stock and the ...

NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 15.78 3.45 21.83 28.62 17.28 12.10 29.11 21.60 38.11 3.67 0.00 0.00 23.53 4.04 17.40 13.36 10.42 15.73 25.56 22.20 28.10 1.73 0.38 0.00 13.68 2.49 18.22 24.04 10.53 19.54 16.46 11.44 21.05 1.42 0.37 0.00 -105.43 1.19 -1.12 2.77 -0.54 1.66 4.14 -1.22 -3.83 2.12 0.63 0.00 -28.48 12.36 -43.40 -33.00 -26.81 41.83 -90.02 -93.21 -7.82 2.54 0.00 0.00 Add More Meeting Date Announced on Purpose Details Apr 27, 2023 Apr 19, 2023 Board Meeting Audited Results Mar 16, 2023 Mar 09, 2023 Board Meeting Interim Dividend Jan 27, 2023 Jan 13, 2023 Board Meeting Quarterly Results Oct 21, 2022 Oct 14, 2022 Board Meeting Quarterly Results Aug 04, 2022 Jul 22, 2022 Board Meeting Quarterly Results • About Glenmark Life Glenmark Life Sciences Ltd., incorporated in the year 2011, is a Small Cap company (having a market cap of Rs 7,372.46 Crore) operating in Pharmaceuticals sector. Glenmark Life Sciences Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2022. For the quarter ended 31-03-2023, the company has reported a Standalone Total Income of Rs 624.16 Crore, up 14.03 % from last quarter Total Income of Rs 547.34 Crore and up 20.23 % from last year same quarter Total Income of Rs 519.15 Crore. Company has reported net profit after tax of Rs 146.36 Crore in latest quarter. The company’s top management incl...

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. It operates through the India, North America, Latin America, Europe, and Rest of the World geographical segments. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India. Glenmark Pharma has completed a long-term inverted Head & shoulders pattern. It is now looking bullish with an upside move of INR 500 from current levels. Almost 2x. At present it is at the 0.5 resistance level of the Fibonacci chart Glenmark Pharma has completed a long-term inverted Head & shoulders pattern. It is now looking bullish with an upside move of INR 500 from current levels. Almost 2x. At present it is at the 0.5 resistance level of the Fibonacci chart One can accumulate this in range of 550-650 with the Sl Of ₹490 and Target of 950 and 1050 good breakout can be seen on a quaterly chart.. lets see if it sustains One can accumulate this in range of 550-650 with the Sl Of ₹490 and Target of 950 and 1050 good breakout can be seen on a quaterly chart.. lets see if it sustains In Gujarati “ Bhav is Bhagwan ” Disclaimer : I am not a SEBI registered Analyst. Please do your own Analysis before taking any trade/investment. The above view is just for educational purpose only. In Gujarati “ Bhav is Bhagwan ” Disclaimer : I am not a SEBI registered Analyst. Please do your own Analysis before taking any trade/investment. Th...